Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Dendritic cells (DC) have a critical effect on the outcome of adaptive immune responses against growing tumors. Whereas it is generally assumed that the presence of phenotypically mature DCs should promote protective antitumor immunity, evidence to the contrary does exist. We describe here a novel mechanism by which tumor-infiltrating dendritic cells (TIDC) actively contribute to the suppression of protective CD8(+) T-cell-based antitumor immunity. Using the BALB/NeuT model of spontaneously arising mammary carcinoma, we found that canonical MHC II(+)/CD11b(+)/CD11c(high) TIDCs act as regulatory DCs to suppress CD8(+) T-cell function, resulting in diminished T-cell-based antitumor immunity in vivo. Stimulation of naive T cells with regulatory TIDCs resulted in an altered cell fate program characterized by minimal T-cell expansion, impaired IFNgamma production, and anergy. Suppression by regulatory TIDCs overcame stimulatory signals provided by standard DCs, occurred in the absence of cognate interactions with T cells, and was mediated primarily by arginase metabolism of l-arginine. Immunosuppressive TIDCs were found in every murine tumor type examined and were phenotypically distinct from tumor-infiltrating CD11c(int-low)/CD11b(+)/Gr-1(+) myeloid-derived suppressor cells. Thus, within the tumor microenvironment, MHC II(+) TIDCs can function as potent suppressors of CD8(+) T-cell immunity.

[1]  C. Reis e Sousa Dendritic cells in a mature age , 2006, Nature reviews. Immunology.

[2]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[3]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[4]  J. Ochoa,et al.  Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine* , 2002, The Journal of Biological Chemistry.

[5]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[6]  H. Groux,et al.  Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. , 2003, Immunity.

[7]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[8]  David Pozo,et al.  Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[10]  J. Blay,et al.  Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer , 2004, Clinical Cancer Research.

[11]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[12]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[13]  Lu Shi-min,et al.  Amino Acid Regulation of Gene Expression , 2006 .

[14]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[15]  P. Allen,et al.  Rapid Maturation of Effector T Cells in Tumors, but Not Lymphoid Organs, during Tumor Regression , 2007, PloS one.

[16]  A. Yang,et al.  Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. , 2003, Cancer research.

[17]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[18]  P. Allen,et al.  T Cell-Mediated Delay of Spontaneous Mammary Tumor Onset: Increased Efficacy with In Vivo versus In Vitro Activation1 , 2005, The Journal of Immunology.

[19]  P. Kaye,et al.  Stromal cells direct local differentiation of regulatory dendritic cells. , 2004, Immunity.

[20]  Hua Tang,et al.  Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells , 2004, Nature Immunology.

[21]  P. Allen,et al.  Priming in the Presence of IL-10 Results in Direct Enhancement of CD8+ T Cell Primary Responses and Inhibition of Secondary Responses1 , 2005, The Journal of Immunology.

[22]  D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[23]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[24]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[25]  Lin Zhang,et al.  Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004, Nature Medicine.

[26]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[27]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase in immune suppression and cancer. , 2007, Current cancer drug targets.

[28]  C. Aspord,et al.  Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development , 2007, The Journal of experimental medicine.

[29]  M. Colombo,et al.  IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.

[30]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[31]  L. Old,et al.  Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma , 1977, The Journal of experimental medicine.

[32]  Katsuaki Sato,et al.  Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. , 2003, Immunity.

[33]  J. Banchereau,et al.  In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas , 1999, The Journal of experimental medicine.

[34]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[35]  J. Connolly,et al.  Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. , 2007, Immunity.

[36]  P. Allen,et al.  Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. , 2003, International immunology.

[37]  P. Allen,et al.  No Intrinsic Deficiencies in CD8+ T Cell-Mediated Antitumor Immunity with Aging1 , 2004, The Journal of Immunology.

[38]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[39]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[40]  C. Chiang,et al.  A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. , 2007, The Biochemical journal.

[41]  E. Gilboa DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[42]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[43]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[44]  J. Blay,et al.  Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86−Langerin‐ and CD1a+CD86+Langerin+ phenotypes , 2004, International journal of cancer.

[45]  R. Offringa,et al.  Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 , 2004, The Journal of Immunology.

[46]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.